Cinclus Pharma
17.698
SEK
-0.01 %
CINPHA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-0.01%
-12.02%
-17.22%
-23.07%
-46.23%
-
-
-
-45.72%
Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.
Read moreMarket cap
838.75M SEK
Turnover
366K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
20/2
2025
Annual report '24
19/5
2025
Interim report Q1'25
22/5
2025
General meeting '25
Invitation to presentation of Cinclus Pharma’s fourth quarter report 2024
Finansinspektionen: Flaggningsmeddelande i Cinclus Pharma Holding AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Antal aktier och röster i Cinclus Pharma
Number of shares and votes in Cinclus Pharma
Linaprazan glurate får marknadsföringstillstånd i Kina
Linaprazan glurate receives marketing approval in China
Emission och återköp av C-aktier
Issue and repurchase of class C shares
![Avanza Börsdag - 28 Nov 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/4e22caf8-db64-44d0-872b-b9c35dbdf136.png)